DelveInsight’s, “Eosinophilic Esophagitis Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eosinophilic Esophagitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Eosinophilic Esophagitis Pipeline Report

• DelveInsight’s Eosinophilic Esophagitis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Eosinophilic Esophagitis treatment.
• The leading companies working in the Eosinophilic Esophagitis Market include AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeutics, EsoCap, Aqilion, Serpin Pharma, and others.
• Promising Eosinophilic Esophagitis Pipeline Therapies in the various stages of development include Tezepelumab, Etrasimod, Reslizumab, Dupilumab, ESO-101, NDX-3315, and others.
• September 2023: Ellodi Pharmaceuticals LP announced a study of phase 3 clinical trials for APT-1011. This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension. This study will evaluate the efficacy and safety of APT-1011 3 mg administered HS (hora somni, at bedtime) for the induction of response to treatment (symptomatic and histologic) over 24 weeks. The open-label extension will continue to evaluate long-term safety in subjects who consent to continue on open-label treatment with APT-1011.
• September 2023: Celgene announced a study of phase 3 clinical trials for CC-93538. This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.

 

Request a sample and discover the recent advances in Eosinophilic Esophagitis Treatment Drugs @ Eosinophilic Esophagitis Pipeline Report

 

In the Eosinophilic Esophagitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Eosinophilic Esophagitis (EoE) occurs as a result of an immunogenic reaction to various antigens which are commonly found in food and air. There is a strong genetic component involved in the pathogenesis of EoE and a high concordance reported for EoE among family members. Study reported that the gene responsible for EoE was TSLP which is located in the 5q22 region of male X chromosome. TSLP stimulates Th2 cells and induces eotaxin-3.

 

Eosinophilic Esophagitis Overview

Eosinophilic esophagitis (EoE) is a chronic disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus. The esophagus is the tube that carries food from the mouth to the stomach. Eosinophils can be found in the esophagus in response to various stimuli or antigen.

 

Find out more about Eosinophilic Esophagitis Therapeutics Assessment @ Eosinophilic Esophagitis Preclinical and Discovery Stage Products

 

Eosinophilic Esophagitis Emerging Drugs Profile

• APT-1011: Ellodi Pharmaceuticals. 

 

DelveInsight’s Eosinophilic Esophagitis Pipeline Report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Eosinophilic Esophagitis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

 

Eosinophilic Esophagitis Pipeline Products have been categorized under various Molecule types such as

• Peptide
• Protein
• Propylene glycols
• Cell Therapy

 

Eosinophilic Esophagitis Pipeline Therapeutics Assessment

There are approx. 18+ key companies which are developing the Eosinophilic Esophagitis therapies. The Eosinophilic Esophagitis companies which have their Eosinophilic Esophagitis drug candidates in the most advanced stage, i.e. Phase III include, Ellodi Pharmaceuticals.

 

Learn more about the emerging Eosinophilic Esophagitis Pipeline Therapies @ Eosinophilic Esophagitis Clinical Trials Assessment

 

Scope of the Eosinophilic Esophagitis Pipeline Report

• Coverage- Global
• Eosinophilic Esophagitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Eosinophilic Esophagitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Eosinophilic Esophagitis Companies- AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeutics, EsoCap, Aqilion, Serpin Pharma, and others.
• Eosinophilic Esophagitis Pipeline Therapies- Tezepelumab, Etrasimod, Reslizumab, Dupilumab, ESO-101, NDX-3315, and others.

 

Dive deep into rich insights for new drugs for Eosinophilic Esophagitis Treatment, Visit @ Eosinophilic Esophagitis Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Eosinophilic Esophagitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Eosinophilic Esophagitis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Benralizumab: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IRL201104: Revolo Biotherapeutics
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Mometasone: EsoCap
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. AQ280: Aqilion
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. SP 16: Serpin Pharma
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Eosinophilic Esophagitis Key Companies
24. Eosinophilic Esophagitis Key Products
25. Eosinophilic Esophagitis- Unmet Needs
26. Eosinophilic Esophagitis- Market Drivers and Barriers
27. Eosinophilic Esophagitis- Future Perspectives and Conclusion
28. Eosinophilic Esophagitis Analyst Views
29. Eosinophilic Esophagitis Key Companies
30. Appendix

 

For further information on the Eosinophilic Esophagitis Pipeline therapeutics, reach out to Eosinophilic Esophagitis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market